batirtze-areitio Batirtze Areitio Batirtze has over 5 years of experience in the biopharma and biotech industries. She joined ApexOnco in 2025 after working as an analyst at OncologyPipeline. She is a graduate of the University of Navarra, where she earned a degree in biochemistry. FDA knocks back subcutaneous Rybrevant 17 December 2024 Foghorn goes quiet on non-selective project 16 December 2024 Checkpoint's latecomer could draw interest 16 December 2024 BeiGene is next into MAT2A inhibition 13 December 2024 ASH 2024 – the BTK degraders are neck and neck 11 December 2024 ASH 2024 – GSK's Blenrep Dreamm gets better 10 December 2024 ASH 2024 – full steam ahead for arlo-cel 10 December 2024 ASH 2024 – Affimed plays up AFM28's safety, despite one death 9 December 2024 Load More